Jeremy Chen

Arsenal Biosciences (United States) — United States

Medicine · Health Sciences

1h-index3citations11works0.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(8), Monoclonal and Polyclonal Antibodies Research(2), Biosimilars and Bioanalytical Methods(2), CRISPR and Genetic Engineering(1), 3D Printing in Biomedical Research(1)

Publications11 total

245 Synthetic pathway activators (SPA) enhance CAR-T activity against solid tumors by reducing T cell exhaustion and increasing functional persistence in preclinical studies
Regular and Young Investigator Award Abstracts·2025Open Access
256 Preclinical development of AB-3028, a logic-gated engineered CAR T cell product intended for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Regular and Young Investigator Award Abstracts·2025Open Access
258 Programmable circuit T cells encoding multiplexed shRNAs and logic-gates for mCRPC
Regular and Young Investigator Award Abstracts·2025Open Access
Abstract 6395: Synthetic pathway activators enhance CAR-T functional persistence and prevent T cell exhaustion
Cancer Research·2025· 1 cited
Abstract B037: AB-2100, a PSMA-inducible CA9-specific CAR T cell product intended for the treatment of ccRCC provides long-term tumor responses in preclinical mouse model
Cancer Immunology Research·2024· 1 cited
Abstract 38: AB-2100, a PSMA-inducible CA9-specific CAR T cell product for the treatment of ccRCC provides long-term tumor responses in preclinical mouse model
Cancer Research·2024
Development of AB-2100, an autologous integrated circuit T (ICT) cell therapy targeting CA9 intended for the treatment of ccRCC.
Journal of Clinical Oncology·2024· 1 cited
301 Preclinical development of AB-2100, a PSMA neovasculature-inducible CA9 CAR resistant to FASL and TGFb mediated suppression for the treatment of ccRCC
Regular and Young Investigator Award Abstracts·2023Open Access
259 Discovery of synthetic signaling pathway receptors that increase the potency of CAR-T cells through optimized STAT activity
Regular and Young Investigator Award Abstracts·2023Open Access
Abstract 1768: Multiplexed shRNA cassettes targeting orthogonal pathways (FAS/PTPN2/TGFBR) enhance the potency of integrated circuit T cells (ICTs) in multiple solid tumor models
Cancer Research·2023
Abstract 4073: Tunable STAT activation by synthetic pathway activators (SPAs) increases engineered T-cell potency and persistence
Cancer Research·2023

Frequent Co-authors

Suchismita Mohanty(11), Alma Gomez(11), Beatriz Millare(10), Thomas J. Gardner(9), Vince Thomas(9), Levi Gray-Rupp(8), W. Nicholas Haining(8), Stanley Zhou(7), Angela Boroughs(7), Aaron Cooper(6), Nickolas Attanasio(5), Amanda Fearon(5), Irene Scarfò(4), Marvin Chew(4), Michelle Nguyen(4), Vibhavari Sail(4), Jennifer McDevitt(4), Anzhi Yao(4), Ashley Cass(4), David DeTomaso(4)